["Psycho-Oncology, Volume 35, Issue 5, May 2026. ", "\nABSTRACT\n\nBackground\nImmune‐checkpoint Inhibitors (ICIs) are increasingly used in advanced cancers and can be associated with immune‐related adverse events (irAEs).\n\n\nAims\nThis study examined the association between anxiety and depression, irAEs, and overall survival in a national cohort of ICI‐treated cancer survivors.\n\n\nMethods\nThis retrospective cohort study used data from 8671 2‐year survivors following ICI treatment with advanced melanoma, lung, colorectal, head and neck, and bladder cancers from a nationwide de‐identified electronic health record‐derived database. Bivariate tests, Kaplan‐Meier curves, and multivariable logistic regressions were conducted using R.\n\n\nResults\nThe majority (79%, N = 6820) did not have irAEs, anxiety, or depression. The landmark analysis observed that accounting for covariates, irAEs were associated with anxiety or depression (aOR: 1.70, 95% CI: 1.41, 2.06, p < 0.001) in the first 2 years after ICIs. Female sex (aOR: 1.46, 95% CI: 1.24, 1.73, p < 0.001), poorer functional status (ECOG = 2: 1.47, 95% CI: 1.06, 2.04, p = 0.022), Medicaid coverage (aOR: 1.54, 95% CI: 1.08, 2.18, p = 0.016), and being seen in an academic practice setting (aOR: 3.62, 95% CI: 3.02, 4.35, p < 0.001) were associated with greater odds of anxiety/depression diagnoses compared with male sex, ECOG = 0, Medicare, and community practice settings. Non‐white survivors who experienced an irAE had lower odds of experiencing anxiety/depression (aOR: 0.58, 95% CI: 0.45, 0.46, p < 0.001) compared with White survivors.\n\n\nConclusions\nFew studies have examined the relationship between anxiety and depression and irAEs in a national sample. Findings have implications for survivorship quality of life and integrated mental health care delivery.\n\n"]